İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

alk-abelló ag - moniliella allergeni estratto di avena elatior, dactylis glomerata, splinter pratensis, phleum pratense, poa pratensis, lolium perpetuo) - depotsuspension per iniezione - moniliella allergeni estratto di avena elatior, dactylis glomerata, splinter pratensis, phleum pratense, poa pratensis, lolium costante) 100000 u., l'alluminio per aluminii hydroxidum hydricum per adsorptionem, natrii hydroxidum, natrii chloridum, natrii hydrogenocarbonas, phenolum, acqua ad iniectabilia q.s. per una sospensione pro 1 ml corresp., sodio 2.18 mg. - iposensibilizzazione - allergeni: terapeutico,

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

haleon schweiz ag - lidocaini hydrochloridum monohydricum, diphenhydramini hydrochloridum, benzalkonii chloridum, levomentholum, dexpanthenolum - gel - lidocaini hydrochloridum monohydricum 20 mg, diphenhydramini hydrochloridum 20 mg, benzalkonii chloridum 10 mg, levomentholum 20 mg, dexpanthenolum 30 mg, hydroxypropylcellulosum, alcohol isopropylicus, aqua purificata, ad gelatum pro 1 g. - punture di insetti e irritazioni della pelle - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

haleon schweiz ag - lidocaini hydrochloridum monohydricum, diphenhydramini hydrochloridum, benzalkonii chloridum, levomentholum - soluzione per l'applicazione sulla pelle - lidocaini hydrochloridum monohydricum 10 mg, diphenhydramini hydrochloridum 10 mg, benzalkonii chloridum 10 mg, levomentholum 20 mg, dexpanthenolum, ethanolum 96 per centum 300 mg, aether, alcohol isopropylicus, glycerolum, ammoniae solutio concentrata, aqua purificata ad solutionem pro 1 ml. - per il trattamento di punture di insetti - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

alk-abelló ag - acari allergeni extractum, acari allergeni extractum (dermatophagoides pteronyssinus), acari allergeni extractum (dermatophagoides farinae) - polvere orale - praeparatio cryodesiccata: acari allergeni extractum 12 u. ut acari allergeni extractum (dermatophagoides pteronyssinus) et acari allergeni extractum (dermatophagoides farinae), gelatina, mannitolum 12.7 mg, natrii hydroxidum corresp. natrium 0.14 mg, pro dosi. - iposensibilizzazione per gli acari della polvere, i pazienti dai 12 ai 65 anni - allergeni: terapeutico,

İtalya - İtalyanca - Ministero della Salute

laboratori nutergia -

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinoma, polmone non a piccole cellule - agenti antineoplastici - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinoma, polmone non a piccole cellule - agenti antineoplastici - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinoma, polmone non a piccole cellule - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

alk-abelló ag - pollinis allergeni extractum (betula pendula) - polvere orale - praeparatio cryodesiccata: pollinis allergeni extractum (betula pendula) 12 u., gelatina, mannitolum, natrii hydroxidum, pro dosi corresp., natrium 0.49 mg. - allergische rhinitis und/oder konjunktivitis - allergeni: terapeutico,

İsviçre - İtalyanca - OFAG-BLW (Bundesamt für Landwirtschaft)

renovita ag - triclopir; calcium dodecylbenzene sulfonate; 1-butanolo; hydrocarbons, c11-c14, n-alkanes, isoalkanes, cyclics, <2% aromatics - ec concentrato emulsionato - erbicida